Follow us on LinkedIn - https://www.linkedin.com/company/fatty-liver-alliance/
Video Presentations
Welcome and introduction to the agenda
Michael Betel, Fatty Liver Alliance
Marko Korenjak, ELPA
Juan Manuel Mendive, European Society for Primary Care Gastroenterology
.jpeg/:/cr=t:7.48%25,l:0%25,w:100%25,h:85.04%25/rs=w:1209,h:605,cg:true)
Understanding MASLD and MASH and the relationship between - Primary Care and the Hepatologist:
- Define MASLD and MASH using current, practical terminology.
- Identify key screening criteria and risk factors for fatty liver disease in primary care.
- Summarize updated guidelines and nomenclature relevant to MASLD and MASH.
Presenter: Jörn Schattenberg, University Medical Center Homburg
MASLD/MASH: is primary care Ready to automate?
Professor Lazarus framed MASLD and MASH as conditions that primary care is uniquely positioned to address. Central to his message was the need to normalize people-first language, automate early detection, and embed liver health into routine metabolic care.
He emphasized that while imaging will ultimately be required for many patients, meaningful progress can already be made using laboratory-based tools, particularly when testing pathways are automated. MASLD should be viewed as a core manifestation of metabolic dysfunction, closely linked with obesity, type 2 diabetes, and cardiovascular risk, rather than a siloed liver condition.
Presenter: Professor Jeffery V. Lazarus, ISglobal
MASLD/MASH: is primary care Ready to automate?
At the European Primary Care MASLD/MASH Summit, Louise Campbell MSc (AP), RMN, RN, FRCP delivered a highly practical session focused on one clear goal: making liver health part of everyday primary care, without adding extra appointments or burden.
Her message was simple and powerful. Most patients do not have advanced liver disease. They have poor liver health, often silent, often overlooked, and frequently reversible when found early.
Key takeaways from Louise’s session:
• Liver health belongs in routine care, diabetes reviews, hypertension checks, weight management, and women’s health visits
• Start simple. Use FIB-4 as a gateway test, followed by ELF or transient elastography when indicated
• Ultrasound alone does not stage fibrosis and should not be relied upon for risk assessment
• Non-invasive tests are not just diagnostic tools. They enable real-time, patient-centered conversations that drive lifestyle change
• Most patients fear stigma, cirrhosis, or irreversible disease. Clear, non-judgmental language changes engagement
• Visual tools like traffic-light coding help patients understand risk and remember progress
• Liver disease is reversible for many patients when identified early
• Women, particularly post-menopause, represent a rapidly growing and often missed at-risk group
Lifestyle Recommendations in MASLD/MASH: Practical Pearls for Busy Primary Care
At the European FLA Primary Care MASLD/MASH Summit, Prof. Shira Zelber Sagi delivered a practical, evidence-based presentation on implementing lifestyle care in real-world primary care. Moderated by Professor Jeffrey V. Lazarus, the session focused on translating strong evidence into patient-centered action.
First European Primary Care MASH Summit: Summaries Above
First Annual European Primary Care MASLD/MASH Summit
Overall Learning Objectives:
1. Recognize and diagnose fatty liver disease, including MASLD and MASH, in at-risk patient populations through appropriate screening and assessment tools.
2. Select and interpret appropriate diagnostic investigations to evaluate suspected cases of fatty liver disease.
3. Implement evidence-based treatment strategies for patients with hepatic steatosis, tailoring interventions to individual risk profiles and disease severity.
4. Identify and refer patients with advanced or high-risk fatty liver disease to specialized care for further management.
MODERATOR: JEFFREY LAZARUS
Thursday, December 4, 2025.
6:00 p.m. - 6:05 p.m.
Welcome & Opening Remarks Michael Betel, Fatty Liver Alliance
Marko Korenjak, European Liver Patients’ Association
Juan Manuel Mendive, European Society For Primary Care Gastroenterology (ESPCG)
6:05 p.m. - 6:30 p.m.
Understanding MASLD and MASH and the relationship between Primary Care and the Hepatologist
- Define MASLD and MASH using current, practical terminology.
- Identify key screening criteria and risk factors for fatty liver disease in primary care.
- Summarize updated guidelines and nomenclature relevant to MASLD and MASH.
Jörn Schattenberg, University Medical Center Homburg
6:30 p.m. - 7:00 p.m.
Primary Care Toolbox: Managing Fatty Liver in Daily Practice
- Select appropriate laboratory and non-invasive tests for the assessment of fatty liver disease.
- What labs to order
- Demonstrate how to integrate liver health assessments into routine patient visits.
- Interpret results from NITs (FIB-4, Transient Elastography, ultrasound, ELF, and non-invasive scores) and determine when to use each tool.
- Apply workflow strategies to optimize efficiency and improve patient care in primary care settings.
Louise Campbell, Tawazun Health
Jeffrey V. Lazarus, Barcelona Institute for Global Health (ISGLOBAL)
7:00 p.m. - 7:25 p.m.
The Patient Voice: MASLD/MASH Real-World Experience
- Describe common barriers patients face in accessing care for MASLD/MASH (e.g., stigma, confusion, fear).
- Discuss patient experiences and factors that contributed to successful management.
- Assess the impact of primary care interventions on patient outcomes.
José Willemse, Liver Patients International
Una Keightley, Dr. Stephen A. Harrison Advocacy Fellow
7:25 p.m. - 7:55 p.m.
Lifestyle Rx: Pearls for a busy Primary Care Practice
- Addressing real world nutritional advice – Practical strategies for Primary Care
- Addressing real world exercise advice - Practical strategies for Primary Care
- Recommend practical nutritional and lifestyle strategies for patients with fatty liver disease.
- Address patient challenges and stigma related to lifestyle modification.
- Demonstrate brief, effective lifestyle interventions suitable for busy clinical settings
Shira Zelber-Sagi Shira, University of Haifa, EASL, researcher at GNC
Jonathan Stine, Penn State Health Milton S. Hershey Medical Center
7:55 p.m. - 8:25 p.m.
Integrating Available Treatment Approaches in Primary Care for management of Fatty Liver disease
- Review the role of GLP-1s, statins, insulin sensitizers, and emerging therapies in MASLD/MASH management.
- Evaluate medication choices considering comorbidities such as T2D, obesity, CKLM and bariatric surgery
- Summarize current and upcoming guidelines for pharmacologic management.
Aleksander Krag, Odense University Hospital
Vlad Ratziu, Hospital Pitié salpêtrière, ICAN
8:25 p.m. - 8:55 p.m.
Case-Based Panel: What Would You Do?
- Analyze real-world cases to identify appropriate diagnostic and management strategies for diabetes and obesity
- Evaluate patient with advanced fibrosis on Transient Elastography but no symptoms
- Evaluate Young patient with obesity and normal liver enzymes
- Differentiate between patients who require specialist referral and those manageable in primary care.
- Formulate individualized care plans based on case scenarios.
James KIM, University of Calgary
Aleksander Krag, Odense University Hospital
Vlad Ratziu, Hospital Pitié salpêtrière, ICAN
Shira Zelber-Sagi Shira, University of Haifa, EASL, researcher at GNC
Una Keightley, Dr. Stephen A. Harrison Advocacy Fellow
8:55 p.m. - 9:00 p.m.
Closing Remarks: Primary Care as Liver Health Leaders Michael Betel, Fatty Liver Alliance